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Abstract: Late-onset Alzheimer’s disease (LOAD), the most common cause of dementia, and a
huge global health challenge, is a neurodegenerative disease of uncertain aetiology. To deliver
effective diagnostics and therapeutics, understanding the molecular basis of the disease is essential.
Contemporary large genome-wide association studies (GWAS) have identified over seventy novel
genetic susceptibility loci for LOAD. Most are implicated in microglial or inflammatory pathways,
bringing inflammation to the fore as a candidate pathological pathway. Among the most significant
GWAS hits are three complement genes: CLU, encoding the fluid-phase complement inhibitor
clusterin; CR1 encoding complement receptor 1 (CR1); and recently, C1S encoding the complement
enzyme C1s. Complement activation is a critical driver of inflammation; changes in complement
genes may impact risk by altering the inflammatory status in the brain. To assess complement gene
association with LOAD risk, we manually created a comprehensive complement gene list and tested
these in gene-set analysis with LOAD summary statistics. We confirmed associations of CLU and
CR1 genes with LOAD but showed no significant associations for the complement gene-set when
excluding CLU and CR1. No significant association with other complement genes, including C1S,
was seen in the IGAP dataset; however, these may emerge from larger datasets.
Keywords: complement; complement receptor 1; clusterin; late-onset Alzheimer’s disease; genet-
ics; neuroinflammation
1. Introduction
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly.
Pathologically, AD is a chronic neurodegenerative disease underpinned by neuronal and
synaptic loss, the accumulation of amyloid-β plaques, and neurofibrillary tangles composed
of hyperphosphorylated tau. An important role for neuroinflammation has emerged in
recent years. Evidence includes the presence of activated microglia in the brain innate
immune cells, the presence of inflammatory markers, including complement proteins, in
the brain, cerebrospinal fluid (CSF) and plasma, and the demonstration that chronic use of
anti-inflammatory drugs may reduce disease incidence [1–3]. Perhaps the best evidence
that inflammation may be involved in AD aetiology comes from genome-wide association
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studies (GWAS); many of the genes most strongly associated with AD risk are involved in
inflammation and immunity.
The first causative mutations for AD, identified over 25 years ago in the rare early-
onset familial forms of AD, were in Amyloid precursor protein (APP), Presenilin 1 (PSEN1)
and Presenilin 2 (PSEN2) genes [4–6]. APP, encoded by the APP gene, a broadly expressed
transmembrane protein abundant in the brain, is sequentially cleaved by secretase enzymes.
The precise cleavage patterns determine its propensity to seed Aβ plaques. The presenilin
proteins PSEN1 and PSEN2 are both components of the γ-secretase complex and important
in the function of this enzyme; mutations in the genes encoding these proteins impact the
APP cleavage pathway. The identification of early-onset AD-associated mutations in these
three genes underpins the amyloid cascade hypothesis whereby abnormal APP processing
leading to Aβ plaque formation is considered the key underlying pathology associated
with AD [7]. However, it is important to stress that these mutations are only relevant to
early-onset familial AD which accounts for fewer than 1% of all AD cases. In late-onset
Alzheimer’s disease (LOAD), accounting for the large majority of AD cases, the strongest
genetic risk factor is the presence of the ε4 allele of the gene encoding Apolipoprotein E
(ApoE); ε4 confers increased risk, while the most common allele, ε3, is considered neutral
for AD, and ε2 has a minor protective effect [8–11]. Homozygosity for APOE ε4 confers
an ~11-fold increased risk of LOAD compared to ε3 homozygotes. Precisely how these
variants in APOE impact disease risk remains a subject of ongoing research. ApoE is a
lipoprotein present in biological fluids; therefore, roles in lipid transport and membrane
repair in the brain have been proposed [12].
Over the past decade, large GWAS have identified variants in more than 70 genetic
loci that are associated with LOAD, implicating multiple and diverse biological path-
ways [13–16]. Notably, ~20% of the genes in LOAD risk loci encode proteins with roles
in inflammation and immunity [14,17,18]; many of these are predominantly expressed in
microglia, notably TREM2, ABI3 and PLCG2 [15,19]. From GWAS, it has been shown that
three complement system genes are significantly associated with LOAD: CLU, CR1, and
recently, C1S encoding the classical pathway enzyme C1s was added to this list [13,16,20].
CLU encodes clusterin, a multifunctional plasma protein that regulates the complement
terminal pathway, and CR1 encodes complement receptor 1 (CR1), a receptor for comple-
ment fragments and regulator of activation. These are both regulators of the complement
cascade and provide the impetus for this analysis of complement genetics in LOAD. To
test whether complement genes beyond CLU and CR1 (both genome-wide significant
(GWS) in the International Genomics of Alzheimer’s Project (IGAP) dataset) influence the
risk of LOAD, we compiled a comprehensive complement gene-set containing only those
genes that encoded proteins directly involved in complement activation, regulation, or
recognition. Then, we undertook several methods of pathway analysis to test whether
additional genes within the complement gene-set were associated with LOAD risk.
2. Materials and Methods
2.1. Complement Genes and Gene Exclusion Analyses in LOAD
In order to understand the genetics of the complement pathway in AD, we compiled
a comprehensive gene-set comprising all complement genes and associated regulators and
receptors. Genes were selected for inclusion based upon known biological relevance to the
complement system rather than by using often inaccurate annotations in public databases.
The resultant complement gene-set contained 56 genes, subdivided into their relevant
functional groups (Table 1).
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Table 1. Complement gene list including all complement genes and associated regulators and receptors. Genes are sub-
divided according to pathway; either classical, lectin, amplification loop or terminal and whether they are complement
genes or associated regulators/receptors.
Pathway HGNC Gene Name Entrez Gene ID HGNC Full Gene Name
Classical C1QA 712 complement C1q A chain
Classical C1QB 713 complement C1q B chain
Classical C1QC 714 complement C1q C chain
Classical C1R 715 complement C1r
Classical C1S 716 complement C1s
Classical/Lectin C2 717 complement C2
Classical/Lectin C4A 720 complement C4A (Rodgers blood group)
Classical/Lectin C4B 721 complement C4B (Chido blood group)
Lectin FCN1 2219 ficolin 1
Lectin FCN2 2220 ficolin 2
Lectin FCN3 8547 ficolin 3
Lectin MASP1 5648 mannan binding lectin serine peptidase 1
Lectin MASP2 10747 mannan binding lectin serine peptidase 2
Lectin MBL2 4153 mannose binding lectin 2
Amplification loop CFB 629 complement factor B
Amplification loop CFD 1675 complement factor D
Classical/Lectin/
Amplification loop C3 718 complement C3
Terminal C5 727 complement C5
Terminal C6 729 complement C6
Terminal C7 730 complement C7
Terminal C8A 731 complement C8 α chain
Terminal C8B 732 complement C8 β chain
Terminal C8G 733 complement C8 γ chain
Terminal C9 735 complement C9
Regulator/Receptor C1QBP 708 complement C1q binding protein
Regulator/Receptor C3AR1 719 complement C3a receptor 1
Regulator/Receptor C4BPA 722 complement component 4 binding protein α
Regulator/Receptor C4BPB 725 complement component 4 binding protein β
Regulator/Receptor C5AR1 728 complement C5a receptor 1
Regulator/Receptor C5AR2 27202 complement component 5a receptor 2
Regulator/Receptor CD46 4179 CD46 molecule
Regulator/Receptor CD55 1604 CD55 molecule (Cromer blood group )
Regulator/Receptor CD59 966 CD59 molecule
Regulator/Receptor CFH 3075 complement factor H
Regulator/Receptor CFHR1 3078 complement factor H related 1
Regulator/Receptor CFHR2 3080 complement factor H related 2
Regulator/Receptor CFHR3 10878 complement factor H related 3
Regulator/Receptor CFHR4 10877 complement factor H related 4
Regulator/Receptor CFHR5 81494 complement factor H related 5
Regulator/Receptor CFI 3426 complement factor I
Regulator/Receptor CFP 5199 complement factor properdin
Regulator/Receptor CLU 1191 clusterin
Regulator/Receptor CR1 1378 complement C3b/C4b receptor 1 (Knops blood group)
Regulator/Receptor CR2 1380 complement C3d receptor 2
Regulator/Receptor CSMD1 64478 CUB and Sushi multiple domains 1
Regulator/Receptor ITGAM 3684 integrin subunit αM
Regulator/Receptor ITGAX 3687 integrin subunit α X
Regulator/Receptor SERPING1 710 serpin family G member 1
Regulator/Receptor VTN 7448 Vitronectin
Regulator/Receptor CD93 22918 C1q receptor phagocytosis
Complement-like C1QL1 10882 complement C1q-like 1
Complement-like C1QL2 165257 complement C1q-like 2
Complement-like C1QL3 389941 complement C1q-like 3
Complement-like C1QL4 338761 complement C1q-like 4
Complement-like C1RL 51279 complement C1r subcomponent-like
Complement-like CR1L 1379 complement C3b/C4b receptor 1-like
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2.2. AD Summary Statistics
This study utilised summary statistics from the International Genomics of Alzheimer’s
Project (IGAP). IGAP is a large three-stage study based upon GWAS on individuals of European
ancestry. In stage 1, IGAP used genotyped and imputed data on 11,480,632 single nucleotide
polymorphisms (SNPs) to meta-analyse GWAS datasets consisting of 21,982 Alzheimer’s disease
cases and 41,944 cognitively normal controls from four consortia: the Alzheimer Disease
Genetics Consortium (ADGC); the European Alzheimer’s disease Initiative (EADI); the
Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE);
and the Genetic and Environmental Risk in AD Consortium Genetic and Environmental
Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease
Consortium (GERAD/PERADES). In stage 2, 11,632 SNPs were genotyped and tested
for association in an independent set of 8362 Alzheimer’s disease cases and 10,483 con-
trols. Meta-analyses of variants selected for analysis in stage 3A (n = 11,666) or stage 3B
(n = 30,511) samples brought the final sample to 35,274 clinical and autopsy-documented
Alzheimer’s disease cases and 59,163 controls.
Gene-set analysis was performed using the complement gene-set and stage 1 summary
statistics from the International Genomics of Alzheimer’s Project [14]. The individual and
combined effects of the genome-wide significant (GWS) genes CLU and CR1 within the
complement gene-set were investigated by removing these genes individually and together.
We utilised the most up-to-date publicly available GWAS dataset at the time of writing [14],
and calculated the complement gene-set p-values when including and excluding those
loci that reached genome-wide significance in the IGAP dataset. The recently identified
LOAD-associated C1S variant [13] does not show genome-wide statistical significance in
the IGAP dataset; and therefore was not removed in the gene-set analysis. Complement
gene-sets were tested for enrichment using the IGAP stage 1 summary statistics [14]
in MAGMA version 1.06 [21]. Summary statistics were filtered for common variants
(MAF ≥ 0.01) and all indels and merged deletions were removed; 8,608,484 SNPs were
analysed. Genes were annotated using reference data files from the European population
of Phase 3 of 1000 Genomes, human genome Build 37 using a window of 35 kb upstream
and 10 kb downstream of each gene [22]. Ten thousand permutations were used to estimate
p-values, corrected for multiple testing using the family-wise error rate (FWER). Gene-sets
with a FWER-corrected p-value < 0.05 under the “mean” model for estimating gene-level
associations were reported as significant.
2.3. Complement Risk Score Analysis
A complement risk score combining the effects of all SNPs in the complement gene-set
was produced. POLARIS [23] was used to compute risk scores in GERAD-genotyped
data (3332 cases, 9832 controls) using SNP effect sizes from IGAP stage 1 summary statis-
tics [14,16,20] (excluding GERAD subjects). Linkage disequilibrium (LD) was estimated
from the GERAD data, and POLARIS was used to adjust the scores for LD between SNPs.
The overall association of the complement gene-set with LOAD was determined using a
logistic regression model, adjusting for population covariates, age, and sex. The logistic
regression model included the baseline polygenic risk scores for all SNPs in the model,
thereby testing for any association beyond the baseline polygenic effect.
Data used in the preparation of this article were obtained from the Genetic and En-
vironmental Risk for Alzheimer’s disease (GERAD) Consortium. The imputed GERAD
sample comprised 3177 AD cases and 7277 controls with available age and gender data.
Cases and elderly screened controls were recruited by the Medical Research Council (MRC)
Genetic Resource for AD (Cardiff University; Institute of Psychiatry, London; Cambridge
University; Trinity College Dublin), the Alzheimer’s Research UK (ARUK) Collabora-
tion (University of Nottingham; University of Manchester; University of Southampton;
University of Bristol; Queen’s University Belfast; the Oxford Project to Investigate Mem-
ory and Ageing (OPTIMA), Oxford University); Washington University, St Louis, United
States; MRC PRION Unit, University College London; London and the South East Region
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AD project (LASER-AD), University College London; Competence Network of Dementia
(CND) and Department of Psychiatry, University of Bonn, Germany; the National Institute
of Mental Health (NIMH) AD Genetics Initiative. A total of 6129 population controls were
drawn from large existing cohorts with available GWAS data, including the 1958 British
Birth Cohort (1958BC) (http://www.b58cgene.sgul.ac.uk, accessed on 15 March 2021),
the KORA F4 Study, and the Heinz Nixdorf Recall Study. All AD cases met criteria for
either probable (NINCDS-ADRDA, DSM-IV) or definite (CERAD) AD. All elderly controls
were screened for dementia using the MMSE or ADAS-cog and were determined to be
free from dementia at neuropathological examination or had a Braak score of 2.5 or lower.
Genotypes from all cases and 4617 controls were previously included in the AD GWAS by
Harold and colleagues (2009) [20]. Genotypes for the remaining population controls were
obtained from WTCCC2. Imputation of the dataset was performed using IMPUTE2 and
the 1000 genomes (http://www.1000genomes.org/, accessed on 15 March 2021) Dec2010
reference panel (NCBI build 37.1).
2.4. Likelihood Ratio Analysis
A likelihood ratio test was used to estimate how much of the complement gene-set
effect on LOAD risk was contributed by CLU and CR1, and to test whether there were
residual polygenic effects of the remaining genes from the complement gene-set. The
effects of CLU and CR1 were estimated using a risk score combining all SNPs in the gene,
produced using POLARIS in order to correct for LD. Likelihood ratio tests were used to
compare individual models containing SNPs in CLU and CR1 and models containing the
combined risk conferred by SNPs in the rest of the complement gene-set.
3. Results
3.1. MAGMA Analysis Reveals the Impact of Individual Complement Genes
From the MAGMA gene-set analysis, the complement gene-set comprising all 56 genes
was significantly associated with LOAD (p = 0.011) (Table 2). When the GWAS-significant
genes CLU and CR1 were excluded individually from the gene-set, the complement-minus-
CLU gene-set was not significant (p = 0.057), while the complement-minus-CR1 gene-set
was significant (p = 0.048). As CR1 and CR1L are located next to each other on chromosome
1, and linkage disequilibrium extends between the two genes, we excluded the CR1/CR1L
locus from the gene-set. This gene-set was not significant (p = 0.082). The gene set in which
both CLU and CR1 were excluded from the complement gene-set was not significantly
associated with LOAD (p = 0.170). The signal in the gene-set where CR1L, CLU and CR1
were excluded was reduced compared with the signal derived from the gene-sets in which
CLU and CR1 were removed (Table 2). Taken together, these results suggest that the
LOAD association signal in the complement gene-set is predominantly driven by CLU
and CR1. Given the physical distance between CR1 and CR1L, the use of extended gene
boundaries and that linkage disequilibrium extends across both genes, we cannot resolve
the signal between these two genes in the gene set analysis. Hence, we cannot confirm any
independent contribution from CR1L.
Table 2. Complement gene-set analysis.
Gene-Set Ngenes OR 95% CI p p FWER
Complement Genes 56 1.402 [1.068, 1.841] 0.008 0.011
Complement Genes Minus CLU 55 1.278 [0.969, 1.684] 0.041 0.057
Complement Genes Minus CR1 55 1.288 [0.981, 1.691] 0.034 0.048
Complement Genes Minus CLU, CR1 54 1.172 [0.891, 1.542] 0.129 0.170
Complement Genes Minus CR1, CR1L 54 1.244 [0.943, 1.639] 0.061 0.082
Complement Genes Minus CLU, CR1, CR1L 53 1.127 [0.854, 1.489] 0.199 0.246
Table 2 displays the results from the MAGMA analysis. Gene-sets were corrected
for multiple testing using the family-wise error rate (FWER). The complement gene-set
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is significant (p = 0.011), but this effect is lost when CLU and CR1 are excluded from the
gene-set (p = 0.170). CLU has the largest impact in the complement set, and the association
with AD is predominantly driven by CLU and CR1.
3.2. Risk Score Analysis Supports the Impact of Complement Genes
To further explore the impact of complement genes on LOAD risk, we adopted a
polygenic approach. We first applied risk score analysis to the dataset, then used logistic
regression to explore the association between LOAD and complement gene-set risk scores in
GERAD individuals (Table 3). The complement gene-set as a whole was strongly associated
with AD in this analysis (p = 0.003). Removal of CLU from the gene-set caused the largest
reduction in significance (p = 0.003 vs. p = 0.053). Removal of CR1, or the CR1/CR1L locus
had minimal impact on the significance of association in the gene-set, although when CLU,
CR1 and CR1L were eliminated, the significance was further reduced compared to the
elimination of CLU alone (p = 0.148 vs. p = 0.053) (Table 3). These gene elimination analyses
demonstrated that CLU and CR1 were the major contributors to the risk of LOAD in the
complement gene-set; however, the polygenic approach revealed that CLU was by far
the more significant of these. In these data, the CLU gene shows a stronger association
compared to CR1 (p = 1.03 × 10−5 and p = 1.5 × 10−3, respectively). The joint association
of CLU and CR1 is stronger still (p = 3.88 × 10−7), showing that CLU and CR1 are both
independently associated with AD.
Table 3. Association between Alzheimer’s disease (AD) and complement gene-set risk score.
Gene-Set Ngenes OR 95% CI p
Complement Genes 56 1.090 [1.028, 1.156] 0.003
Complement Genes Minus CLU 55 1.059 [0.998, 1.123] 0.053
Complement Genes Minus CR1 55 1.089 [1.027, 1.155] 0.004
Complement Genes Minus CLU, CR1 54 1.058 [0.997, 1.122] 0.059
Complement Genes Minus CR1, CR1L 54 1.077 [1.015, 1.142] 0.013
Complement Genes Minus CLU, CR1, CR1L 53 1.044 [0.984, 1.107] 0.148
Table 3 displays the results from the risk score analysis; the overall complement risk
score shows an association with AD (p = 0.003). CLU explains the majority of this signal.
3.3. Likelihood Ratio Analysis Confirms No Significant Impact of Other Complement Genes
We next tested complement gene-set effects using likelihood ratio analyses. Models in
which CLU, CR1 and CR1/CR1L were removed individually, showed significant residual
impact in the gene-set (p = 0.0136; p = 0.0091; p = 0.0063 respectively); after removal of CR1
and CLU or CR1, CLU and CR1L, there was no significant residual impact in the gene-set,
demonstrating that there was no significant polygenic effect of the remaining complement
genes in the datasets used (Table 4). These results further support the conclusion that the
complement gene-set association with LOAD is driven predominantly by CLU and CR1,
but with no significant contribution from other complement gene-set members (p = 0.1457;
Table 4).
Table 4 shows the results from these likelihood ratio tests comparing models containing
SNPs in CLU, CR1 and CR1/CR1L only and models containing the combined risk in SNPs in
the remaining complement genes. The p-values demonstrate whether the remaining genes
in the complement explain any additional variation. These results further support the
conclusion that the complement gene-set impact on LOAD risk is predominantly driven by
CLU and CR1.
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Table 4. Likelihood ratio test (LRT) comparing gene-set risk scores.
Models Compared LRT p-Value
(1) CLU
(2) CLU + Complement_minus_CLU 0.0136
(1) CR1
(2) CR1 + Complement_minus_CR1 0.0091
(1) CLU + CR1
(2) CLU + CR1 + Complement_minus_CLU_CR1 0.1457
(1) CR1 + CR1L
(2) CR1 + CR1L + Complement_minus_CR1_CR1L 0.0063
(1) CLU + CR1 + CR1L
(2) CLU + CR1 + CR1L + Complement_minus_CLU_CR1_CR1L 0.1145
4. Discussion
The first evidence implicating the complement system in LOAD came from immunos-
taining of post-mortem brain tissue. Complement components and activation products,
notably C1q, C4b, C3b/iC3b and the membrane attack complex, were present and co-
localised with amyloid plaques and neurofibrillary tangles in the AD brain [24–27]. C3
fragments were shown to opsonise amyloid for phagocytosis by microglia in the brain and
facilitate transport on erythrocytes to the liver [28]. Complement activation is critically
involved in synaptic pruning both in development and in diseases such as AD [29–32]. In
AD mouse models, back-crossing to complement deficiencies has supported the critical role
of complements in neuroinflammation and synapse loss [30,33]. The presence of comple-
ment activation biomarkers in CSF and/or plasma in LOAD suggested that complement
dysregulation occurs early in the disease [2]. The demonstration that complement genes
associated with LOAD provided compelling evidence that the complement was a driver of
disease rather than a secondary event [13,14,16].
To further investigate the roles of complement genes in the risk of LOAD, we compiled
a comprehensive complement gene-set and used a polygenic approach to identify genes
contributing to AD risk. We have demonstrated that the signal for the association of the
complement gene-set with LOAD is explained by the GWS genes CLU and CR1, and not by
other complement genes tested here. This finding was unexpected. Based on knowledge
from other chronic inflammatory diseases, we had hypothesised that many complement
genes might influence LOAD risk. For example, in age-related macular degeneration
(AMD), a retinal disease clinically and pathologically linked to LOAD, genes encoding
complement components C2, C3, FB and C9, and regulators FH and FHR4, all contribute
to risk [34]. Indeed, the demonstration that multiple complement genes can collaborate
to cause dysregulation and disease informed the concept of the “complotype”, the set of
complement gene variants inherited by an individual that dictates complement activity
and disease risk [35]. The genetic associations in these other chronic inflammatory diseases
influence systemic or local complement regulation and/or amplification of activation; these
in turn cause complement dysregulation that drives inflammation. Our demonstration that
the complement genetic signature in LOAD is restricted to the genes encoding clusterin and
CR1 suggests that complement dysregulation is not critical in the disease process. However,
it should be noted that this finding is dependent on the dataset being investigated. At
the time of writing, we utilised the largest publicly available AD GWAS dataset [14].
A recent study by the European AD Biobank, currently a preprint, reported an LOAD
GWAS-significant association with the complement gene C1S [13]; this suggests that larger
datasets and different analytical methods may implicate other complement genes and
further elucidate roles of the complement system in LOAD. Additionally, because of the
highly repetitive nature of a number of the complement loci, for example, the regulators of
complement activation (RCA) clusters on chromosome 1 [36], many complement genes may
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be hidden from standard sequencing technologies; the application of emerging long-range
sequencing methods may reveal additional genetic variation in complement genes linked
to LOAD missed in current GWAS and whole exome/genome sequencing studies using
short read sequencing technologies [37].
Of the complement genes tested here, CLU and CR1 were significantly associated
with LOAD through multiple analytical approaches. Clusterin is a multi-functional plasma
protein; its role in the complement system is to restrict fluid-phase membrane attack
pathway activation [38]; however, beyond the complement system, clusterin functions as
an extracellular chaperone protein, is involved in oxidative stress and cell survival/cell
death pathways, and functions as an apolipoprotein in lipid transport [38–41]. Any one
or several of these functions might underpin the association with LOAD. Four SNPs in
CLU, all intronic and in LD, have been associated with increased LOAD risk (rs11136000,
rs2279590, rs9331888 and rs9331896) [16,20]; evidence to date suggests that these SNPs
impact clusterin synthesis, and hence, plasma clusterin levels. CR1 is a membrane-bound
receptor for complement components (C1q, MBL) and fragments (C3b, C4b). The primary
function of CR1 is as a receptor for C3b/C4b-opsonised immune complexes. CR1 on
erythrocytes sequesters immune complexes and transports them to disposal sites, while
CR1 on phagocytic cells binds opsonised immune complexes and processes them for
elimination via phagocytosis. This latter activity requires a second function of CR1, its
cofactor activity for factor I cleavage of C3b to iC3b the ligand for the phagocytic receptor
CR3. The biological relevance of the C1q/MBL binding functions of CR1 are unclear. The
human CR1 gene is located in the RCA gene cluster on chromosome 1 (1q32); duplications
and deletions in this highly repetitive gene generate multiple isoforms via copy number
variation (CNV). The most common variant, CR1*1 (allele frequency 0.87) comprises 30
tandem repeats of 60–70 amino acid units called short consensus repeats (SCRs), which
are in turn grouped in four homologous sets of seven termed long homologous repeats
(LHRs), each a separate C3b/C4b binding unit. The second most common variant CR1*2
(allele frequency 0.11) is identical to CR1*1 except for the acquisition of an additional LHR,
a “gain-of-function”; this variant increases risk for LOAD by up to 30%, although precisely
how is unclear [14,16,42–44]. It has been suggested that the CR1*2 variant is associated
with lower CR1 expression on erythrocytes, reducing the efficiency of peripheral immune
complex handling and impacting amyloid clearance from the brain [45,46].
Our original analysis suggested that some of the signal from the complement gene-set
might be attributable to the CR1L gene. However, CR1L is immediately adjacent to CR1 and
the SNP signals cannot be resolved, so it is not possible to ascribe an independent signal to
CR1L in this analysis. CR1L encodes a C4b-binding protein comprising 13 SCRs, expressed
predominantly in haematopoietic tissues [47,48]. Its physiological role is unknown, and
evidence mechanistically linking it to LOAD is absent.
5. Conclusions
Taken together, our findings confirm the strong genetic association of the complement
genes CR1 and CLU with LOAD and that there is no statistically significant association
signal for other complement genes apparent in the dataset used for the analysis. CR1
and clusterin are important regulators of the complement pathway, suggesting that its
dysregulation is important in LOAD. The recent GWAS association of C1S with LOAD
demonstrates the potential for missing associations in this complex gene-set and raises
the possibility that other loci may be missed by current large-scale genotyping and short-
read sequencing technologies. Application of long read sequencing technologies could
significantly alter the current landscape of complement system genetics in relation to
LOAD risk.
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